Elizabeth Michel Ortega-Rocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Michel Ortega-Rocha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Lemini-López
Department of Dermatology, Hospital de Especialidades “Dr. Bernardo Sepúlveda Gutiérrez,” Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
3 shared publications - Laura Cecilia Bonifaz Alfonzo
Coordinación de Investigación en Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social
3 shared publications - Angel Juarez-Flores
Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez
1 shared publication - Brenda Hernández-Rico
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad de Investigación en Inmunoquímica. Ciudad de México, México
1 shared publication - Cristina Aguilar Flores
UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico
1 shared publication - César Maldonado-García
Centro Dermatológico “Dr. Ladislao de la Pascua”, Secretaria de Salud de la Ciudad de México, Mexico City 06780, Mexico
1 shared publication
Latest Publications
- Open Access
- 1 November 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100257
The interplay between epidermal barrier distribution, microbiota composition, and immune infiltrate defines and stratifies psoriasis patients and is associated with disease severity
- 1 November 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100257
Open AccessThe interplay between epidermal barrier distribution, microbiota composition, and immune infiltrate defines and stratifies psoriasis patients and is associated with disease severity
- Open Access
- 5 September 2024
- Vol. 62 (suppl 2) , 1-7
[Translational medicine in dermatology: experience in the Specialties Hospital of the 21st Century National Medical Center].
Through multidisciplinary research, translational medicine allows a comprehensive approach to diseases in order to provide patients with adequate treatment, whose aim is personalized and precision medicine. In this context, the Cellular Immunology Laboratory of the Immunochemistry Research Unit, and the Dermatology Service of the 21st Century National Medical Center's Specialties Hospital (Hospital de Especialidades del Centro Médico Nacional Siglo XXI) have achieved a partnership that aspires to provide better quality patient care. This objective is achieved by evaluating the inflammatory skin infiltrates in different pathologies to observe changes in local immunity related to the response to treatment, and with the disease progression distinguish between dermatological diseases, highlight the importance of comprehensive skin care, and make decisions about treatment choice. This article will describe the results obtained from different research protocols (derived from this collaboration) in patients with different dermatoses such as warts, squamous cell carcinoma, mycosis fungoides and psoriasis. The evidence presented highlights the importance of collaborative work between clinical services and research laboratories so that scientific knowledge can be translated towards the comprehensive management of patients and towards personalized and precision medicine.
- 5 September 2024
- Vol. 62 (suppl 2) , 1-7
Open Access[Translational medicine in dermatology: experience in the Specialties Hospital of the 21st Century National Medical Center].
Through multidisciplinary research, translational medicine allows a comprehensive approach to diseases in order to provide patients with adequate treatment, whose aim is personalized and precision medicine. In this context, the Cellular Immunology Laboratory of the Immunochemistry Research Unit, and the Dermatology Service of the 21st Century National Medical Center's Specialties Hospital (Hospital de Especialidades del Centro Médico Nacional Siglo XXI) have achieved a partnership that aspires to provide better quality patient care. This objective is achieved by evaluating the inflammatory skin infiltrates in different pathologies to observe changes in local immunity related to the response to treatment, and with the disease progression distinguish between dermatological diseases, highlight the importance of comprehensive skin care, and make decisions about treatment choice. This article will describe the results obtained from different research protocols (derived from this collaboration) in patients with different dermatoses such as warts, squamous cell carcinoma, mycosis fungoides and psoriasis. The evidence presented highlights the importance of collaborative work between clinical services and research laboratories so that scientific knowledge can be translated towards the comprehensive management of patients and towards personalized and precision medicine.
- Open Access
- 31 July 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-16
Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients
Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory experimental models. However, it is not clear if the pathogenic phenotype could be present in the skin and peripheral blood as well as its possible association to severity in psoriasis. In the lesional skin, we found high infiltration of Th17 cells and the pathogenic phenotype, finding a correlation between the frequency of Th17 cells and the Psoriasis Area and Severity Index (PASI) score. In peripheral blood, we observed a pool of Th17 lymphocytes with potential to acquire pathogenic features. Interestingly, the percentage of pathogenic Th17 cells (CD4+ RORγt+ IFN-γ+) correlates with disease severity. Moreover, we distinguished three groups of patients based on their IL-17/IFN-γ production by Th17 lymphocytes, which seems to be related with a dynamic or stable potential to express these cytokines. Remarkably, we evaluated the cytokine production by Th17 cells as an immunological marker for the adequate selection of biologic therapy. We found that patients analyzed by this immunological approach and treated with antibodies against IL-17 and TNFα showed great improvement depicted by reduction in PASI and Dermatology Life Quality Index (DLQI) score as well as the percentage of Body Surface Area (BSA). Altogether, our results highlight the importance of the assessment of the pathogenic phenotype in Th17 cells as an immune personalized analysis with the potential to support the therapy choice in the clinical practice.
- 31 July 2020
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-16
Open AccessAssociation of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients
Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory experimental models. However, it is not clear if the pathogenic phenotype could be present in the skin and peripheral blood as well as its possible association to severity in psoriasis. In the lesional skin, we found high infiltration of Th17 cells and the pathogenic phenotype, finding a correlation between the frequency of Th17 cells and the Psoriasis Area and Severity Index (PASI) score. In peripheral blood, we observed a pool of Th17 lymphocytes with potential to acquire pathogenic features. Interestingly, the percentage of pathogenic Th17 cells (CD4+ RORγt+ IFN-γ+) correlates with disease severity. Moreover, we distinguished three groups of patients based on their IL-17/IFN-γ production by Th17 lymphocytes, which seems to be related with a dynamic or stable potential to express these cytokines. Remarkably, we evaluated the cytokine production by Th17 cells as an immunological marker for the adequate selection of biologic therapy. We found that patients analyzed by this immunological approach and treated with antibodies against IL-17 and TNFα showed great improvement depicted by reduction in PASI and Dermatology Life Quality Index (DLQI) score as well as the percentage of Body Surface Area (BSA). Altogether, our results highlight the importance of the assessment of the pathogenic phenotype in Th17 cells as an immune personalized analysis with the potential to support the therapy choice in the clinical practice.